The Food and Drug Administration issued an unusual warning letter Thursday to a Canadian drug distributor, contending the company has sent “unapproved” and “misbranded” drugs to consumers in the United States, jeopardizing their safety. The FDA urged U.S. consumers “not to use any medicines from CanaRx,” which supplies drugs to employees of about 500 cities and counties, and private-sector employers seeking discounts on drug prices. The FDA said the drugs include some subject to special rules and restrictions in the U.S. because they are potentially dangerous to users. The FDA action comes amid a growing clamor over high drug prices in the U.S. that included a Senate hearing Tuesday at which top pharmaceutical executives were grilled about the costs. Read moreCities, counties, schools sidestep FDA Canadian drug crackdownPharmaceutical executives grilled in Senate over high drug pricesCancer experts call for curbs on rising drug prices

Source: Washington Post February 28, 2019 21:21 UTC